Purpose: Chronic bacterial prostatitis (CBP) is one of the most common urological diseases in adult males, for which antibiotic therapy is the gold standard treatment. However, long-term therapy has many side effects and results in antibiotic resistance. For these reasons, a new treatment modality, which can replace the traditional antibiotic therapy, is required. Ginsenoside has various confirmed bacterial clearance effects in the respiratory system and on immune modulation. Urovaxom Ⓡ also has confirmed effects on immune modulation, with a preventive effect on recurrent urinary tract infection (UTI). Therefore, the anti-bacterial and synergistic effects of ginsenoside and Urovaxom Ⓡ were evaluated for the treatment of CBP in ananimal model. Materials and Methods: The 60 rats demonstrating CBP were randomly divided into 6 groups; the control, ciprofloxacin, ginsenoside, Urovaxom Ⓡ , ciprofloxacin with ginsenoside, and ciprofloxacin with Urovaxom Ⓡ groups. All drug treatments were conducted for 2 weeks. After treatment, the results were analysed microbiologically and histopathologically. Results: The microbiological cultures of the prostate and urine samples and the histological findings of the prostate demonstrated reduced bacterial growth and improved inflammatory responses in all the experimental groups compared with the control group. The ciprofloxacin, and Urovaxom Ⓡ with ciprofloxacin groups showed statistically significant decreases in bacterial growth and improvements in inflammatory responses compared to the control group (p＜0.05). The ginsenoside with ciprofloxacin group showed no statistical significance (p＞0.05), but the mean difference was very large. Conclusions: Ginsenoside and Urovaxom Ⓡ may be effective materials in CBP treatment, and has synergistic effects as a combination treatment. Therefore, the combination therapy of ginsenoside with ciprofloxacin or Urovaxom Ⓡ with ciprofloxacin will be effective treatments of CBP. (Korean J Urol 2007;48:849-857)
양하여 비뇨기과 의사들과 환자들에게 그 진단과 치료에 어려움을 주고 있다. 1 
